Gujarat Themis Biosyn Profits Soar 35% in Q3 2025

In the third quarter of 2025, Gujarat Themis Biosyn, a pharmaceutical company, has delivered impressive financial results. The company's net profit has risen by 34.91% to Rs 14.26 crore, compared to Rs 10.57 crore in the same period last year. This strong performance is driven by a 21.98% increase in sales, which reached Rs 42.35 crore in the quarter, up from Rs 34.72 crore in the previous year's third quarter.

The company's operating profit margin has also improved, reaching 49.42% in the third quarter of 2025, up from 44.35% in the same period of 2024. This indicates that Gujarat Themis Biosyn has been able to effectively manage its costs and maintain profitability despite the challenging market conditions.

Overall, the company's financial results for the third quarter of 2025 demonstrate its ability to deliver consistent growth and profitability, positioning it well for continued success in the pharmaceutical industry.